{
    "thesis_theoretical": [
        {
            "Thesis0": "The influencer suggests that the company's strong fundamentals and high growth rate are the key reasons for its impressive returns."
        },
        {
            "Thesis1": "The influencer also suggests that despite the significant increase in the stock's price, it still has potential for further growth due to its relatively low PE and PEG ratios."
        },
        {
            "Thesis2": "The influencer also suggests that the company could potentially transition from a small cap to a mid or large cap stock."
        }
    ],
    "thesis_quantitative": [
        {
            "Thesis0": "In the last five years, the stock has given close to 2200% returns."
        },
        {
            "Thesis1": "The company's revenues have been growing at a rate of 26-30%."
        },
        {
            "Thesis2": "The company's earnings per share has been growing at a rate of 44-32%."
        },
        {
            "Thesis3": "The stock's price has increased from 55 Rupees to roughly 700 rupees."
        },
        {
            "Thesis4": "The stock's PE ratio is currently 19, compared to Nifty Pharma PE which is roughly at 31."
        },
        {
            "Thesis5": "The stock's PEG ratio is currently 0.27."
        }
    ],
    "username": "Rahul Jain"
}